iDFS Benefit with Ribociclib Plus Nonsteroidal Aromatase Inhibitor in Patients with HR-positive, HER2-negative Early Breast Cancer By Ogkologos - November 14, 2024 730 0 Facebook Twitter Google+ Pinterest WhatsApp Final invasive disease-free survival results from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR FDA Approves Pembrolizumab for Cutaneous Squamous Cell Carcinoma June 26, 2020 FDA Approves Sacituzumab Govitecan-hziy for HR-positive Advanced Breast Cancer February 15, 2023 Implementation of Door-to-Door HPV-based Cervix Screening Results in Better Attendance of... April 17, 2023 Cómo aprendí a sobrellevar la culpa del superviviente después del cáncer May 4, 2022 Load more HOT NEWS PRO Data Can Help When Deciding Between Neoadjuvant FOLFOX or Fluorouracil-Based... FDA Approves Pembrolizumab for Cutaneous Squamous Cell Carcinoma Efficacy and Safety of Patritumab Deruxtecan in EGFR-mutated NSCLC Resistant to... Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
